Analysts expect Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) to post earnings per share of ($0.62) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Aerie Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.61) and the lowest estimate coming in at ($0.63). Aerie Pharmaceuticals posted earnings of ($0.67) per share during the same quarter last year, which would indicate a positive year over year growth rate of 7.5%. The firm is scheduled to announce its next earnings report on Wednesday, November 1st.

According to Zacks, analysts expect that Aerie Pharmaceuticals will report full-year earnings of ($2.54) per share for the current financial year, with EPS estimates ranging from ($2.60) to ($2.48). For the next financial year, analysts expect that the business will report earnings of ($2.08) per share, with EPS estimates ranging from ($2.39) to ($1.77). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Aerie Pharmaceuticals.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings results on Tuesday, August 1st. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.02.

Several analysts have recently issued reports on AERI shares. Zacks Investment Research downgraded Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Needham & Company LLC reiterated a “buy” rating and set a $65.00 price target on shares of Aerie Pharmaceuticals in a research note on Sunday, September 17th. Stifel Nicolaus reiterated a “buy” rating and set a $70.00 price target on shares of Aerie Pharmaceuticals in a research note on Friday, July 28th. Mizuho reiterated a “buy” rating and set a $70.00 price target on shares of Aerie Pharmaceuticals in a research note on Wednesday, September 20th. Finally, Canaccord Genuity set a $65.00 target price on Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, October 11th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have issued a buy rating to the stock. Aerie Pharmaceuticals currently has an average rating of “Buy” and an average price target of $69.71.

Hedge funds have recently made changes to their positions in the business. AXA bought a new stake in shares of Aerie Pharmaceuticals in the 2nd quarter worth approximately $10,961,000. Goldman Sachs Group Inc. lifted its position in shares of Aerie Pharmaceuticals by 28.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 223,053 shares of the company’s stock worth $10,115,000 after acquiring an additional 49,473 shares during the period. BlackRock Inc. lifted its position in shares of Aerie Pharmaceuticals by 113,376.8% in the 1st quarter. BlackRock Inc. now owns 2,600,888 shares of the company’s stock worth $117,951,000 after acquiring an additional 2,598,596 shares during the period. Boulegeris Investments Inc. lifted its position in shares of Aerie Pharmaceuticals by 5.2% in the 2nd quarter. Boulegeris Investments Inc. now owns 79,525 shares of the company’s stock worth $4,179,000 after acquiring an additional 3,900 shares during the period. Finally, TIAA CREF Investment Management LLC lifted its position in shares of Aerie Pharmaceuticals by 8.5% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 124,238 shares of the company’s stock worth $6,529,000 after acquiring an additional 9,781 shares during the period. Institutional investors own 94.70% of the company’s stock.

Aerie Pharmaceuticals (AERI) traded down 1.40% during trading on Wednesday, reaching $63.50. The company had a trading volume of 525,123 shares. The company’s market capitalization is $2.31 billion. Aerie Pharmaceuticals has a 12 month low of $32.05 and a 12 month high of $66.10. The stock has a 50 day moving average of $57.10 and a 200-day moving average of $51.89.

ILLEGAL ACTIVITY NOTICE: “-$0.62 EPS Expected for Aerie Pharmaceuticals, Inc. (AERI) This Quarter” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/25/0-62-eps-expected-for-aerie-pharmaceuticals-inc-aeri-this-quarter-2.html.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Get a free copy of the Zacks research report on Aerie Pharmaceuticals (AERI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.